Zacks Research Issues Positive Estimate for BHC Earnings

Bausch Health Cos Inc. (NYSE:BHC) – Stock analysts at Zacks Research increased their Q1 2027 earnings per share estimates for Bausch Health Cos in a research report issued to clients and investors on Wednesday, August 19th. Zacks Research analyst Team now expects that the company will post earnings per share of $0.84 for the quarter, up from their prior forecast of $0.80. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.35 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q2 2027 earnings at $0.91 EPS, Q3 2027 earnings at $1.07 EPS, Q4 2027 earnings at $1.02 EPS, FY2027 earnings at $3.84 EPS, Q1 2028 earnings at $0.65 EPS, Q2 2028 earnings at $0.86 EPS and FY2028 earnings at $3.04 EPS.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.30. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%.The business had revenue of $2.83 billion during the quarter, compared to analysts’ expectations of $2.59 billion.

Several other equities research analysts also recently issued reports on BHC. Weiss Ratings upgraded Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, July 31st. Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Royal Bank Of Canada decreased their price objective on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a research report on Monday, April 27th. Finally, Jefferies Financial Group raised Bausch Health Cos to a “hold” rating in a research note on Wednesday, July 22nd. Five analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $8.00.

Bausch Health Cos Stock Performance

BHC stock opened at $6.84 on Friday. Bausch Health Cos has a 1-year low of $4.33 and a 1-year high of $8.00. The company has a current ratio of 1.44, a quick ratio of 1.08 and a debt-to-equity ratio of 54.68. The firm has a market cap of $2.56 billion, a PE ratio of -2.31 and a beta of 0.38. The business’s 50-day moving average price is $5.33 and its two-hundred day moving average price is $5.46.

Insider Transactions at Bausch Health Cos

In other Bausch Health Cos news, insider Aimee J. Lenar sold 36,827 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total transaction of $258,893.81. Following the completion of the transaction, the insider owned 334,853 shares in the company, valued at approximately $2,354,016.59. This represents a 9.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 20.67% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of BHC. Dynamic Technology Lab Private Ltd acquired a new position in Bausch Health Cos during the 1st quarter worth approximately $68,000. Jones Financial Companies Lllp boosted its stake in shares of Bausch Health Cos by 1,548.9% during the 1st quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company’s stock worth $162,000 after buying an additional 23,451 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Bausch Health Cos by 97.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock valued at $6,136,000 after acquiring an additional 467,270 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Bausch Health Cos by 3.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company’s stock valued at $2,102,000 after acquiring an additional 9,834 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Bausch Health Cos by 11.2% in the second quarter. Geode Capital Management LLC now owns 840,418 shares of the company’s stock valued at $5,597,000 after acquiring an additional 84,892 shares during the last quarter. 78.65% of the stock is currently owned by institutional investors.

Key Bausch Health Cos News

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Improving Bausch + Lomb outlook: A recent analysis highlighted Bausch + Lomb’s 9% year-over-year revenue growth in the second quarter, margin expansion and strong operating cash flow. Growth in premium intraocular lenses and branded pharmaceuticals could support a better product mix, higher EBITDA and debt reduction. Bausch + Lomb: The Market Is Pricing The Balance Sheet, Not The Eye-Care Engine
• Neutral Sentiment: Zacks raised multiple earnings forecasts: Zacks Research increased its estimates for 2026 and 2027, including FY2026 EPS from $3.93 to $4.24 and FY2027 EPS from $3.59 to $3.84. Estimates for several quarterly periods through 2028 were also raised modestly. However, Zacks retained a Strong Sell rating, limiting the positive impact of the revisions. Bausch Health Cos analyst coverage
• Negative Sentiment: Insider selling adds pressure: Aimee Lenar sold 36,827 BHC shares for approximately $258,894, reducing her position by 9.91%. The sale was made under a pre-arranged Rule 10b5-1 trading plan, which makes it a less concerning signal than discretionary selling, but it may still weigh modestly on sentiment. Aimee Lenar Sells 36,827 Shares of Bausch Health Cos

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.